Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Potent in vitro inactivation of both free and cell-associated CCR5- and CXCR4-tropic HIV-1 by common commercial soap bars from South Africa.

Jenabian MA, Auvert B, Saïdi H, Lissouba P, Matta M, Bélec L.

J Acquir Immune Defic Syndr. 2010 Aug;54(4):340-2. doi: 10.1097/QAI.0b013e3181e3dbf6.

PMID:
20517160
2.

HIV co-receptors as targets for antiviral therapy.

Schols D.

Curr Top Med Chem. 2004;4(9):883-93. Review.

PMID:
15134547
3.

Inhibition of CXCR4-tropic HIV-1 infection by lipopolysaccharide: evidence of different mechanisms in macrophages and T lymphocytes.

Verani A, Sironi F, Siccardi AG, Lusso P, Vercelli D.

J Immunol. 2002 Jun 15;168(12):6388-95.

4.

Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.

De Clercq E, Schols D.

Antivir Chem Chemother. 2001;12 Suppl 1:19-31.

PMID:
11594685
5.

HIV chemokine receptor inhibitors as novel anti-HIV drugs.

Princen K, Schols D.

Cytokine Growth Factor Rev. 2005 Dec;16(6):659-77. Epub 2005 Jul 6. Review.

PMID:
16005254
6.

Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.

Fransen S, Bridger G, Whitcomb JM, Toma J, Stawiski E, Parkin N, Petropoulos CJ, Huang W.

Antimicrob Agents Chemother. 2008 Jul;52(7):2608-15. doi: 10.1128/AAC.01226-07. Epub 2008 Apr 28.

7.

CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection.

Zaitseva MB, Lee S, Rabin RL, Tiffany HL, Farber JM, Peden KW, Murphy PM, Golding H.

J Immunol. 1998 Sep 15;161(6):3103-13.

8.
9.

Partial inactivation of CCR5- and CXCR4- tropic HIV-1 by human urine.

Auvert B, Jenabian MA, Saidi H, Lissouba P, Bélec L.

Arch Virol. 2011 Dec;156(12):2181-6. doi: 10.1007/s00705-011-1114-9. Epub 2011 Sep 24.

PMID:
21947506
10.

Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6.

Grivel JC, Ito Y, Fagà G, Santoro F, Shaheen F, Malnati MS, Fitzgerald W, Lusso P, Margolis L.

Nat Med. 2001 Nov;7(11):1232-5.

PMID:
11689888
11.

CXCR4-tropic HIV-1 suppresses replication of CCR5-tropic HIV-1 in human lymphoid tissue by selective induction of CC-chemokines.

Ito Y, Grivel JC, Chen S, Kiselyeva Y, Reichelderfer P, Margolis L.

J Infect Dis. 2004 Feb 1;189(3):506-14. Epub 2004 Jan 20.

PMID:
14745709
12.

The synthetic peptide WKYMVm attenuates the function of the chemokine receptors CCR5 and CXCR4 through activation of formyl peptide receptor-like 1.

Li BQ, Wetzel MA, Mikovits JA, Henderson EE, Rogers TJ, Gong W, Le Y, Ruscetti FW, Wang JM.

Blood. 2001 May 15;97(10):2941-7.

13.

Susceptibility of diverse primary HIV isolates with varying co-receptor specificity's to CXCR4 antagonistic compounds.

Owen SM, Rudolph D, Schols D, Fujii N, Yamamoto N, Lal RB.

J Med Virol. 2002 Oct;68(2):147-55.

PMID:
12210401
14.

Assessing chemokine co-receptor usage in HIV.

Coakley E, Petropoulos CJ, Whitcomb JM.

Curr Opin Infect Dis. 2005 Feb;18(1):9-15. Review.

PMID:
15647694
15.

A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor.

Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, Doms RW, O'Brien WA.

J Exp Med. 1997 Oct 20;186(8):1395-400.

16.

Lineage-specific expression of human immunodeficiency virus (HIV) receptor/coreceptors in differentiating hematopoietic precursors: correlation with susceptibility to T- and M-tropic HIV and chemokine-mediated HIV resistance.

Chelucci C, Casella I, Federico M, Testa U, Macioce G, Pelosi E, Guerriero R, Mariani G, Giampaolo A, Hassan HJ, Peschle C.

Blood. 1999 Sep 1;94(5):1590-600.

17.

Genotypic coreceptor analysis.

Sierra S, Kaiser R, Thielen A, Lengauer T.

Eur J Med Res. 2007 Oct 15;12(9):453-62. Review.

PMID:
17933727
20.

The role of the thymus in HIV infection: a 10 year perspective.

Ho Tsong Fang R, Colantonio AD, Uittenbogaart CH.

AIDS. 2008 Jan 11;22(2):171-84. Review. No abstract available.

PMID:
18097219

Supplemental Content

Support Center